Evidence map›Paper›PMID 11895983›Full record

ArticleInfection and immunity2002

Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci.

James B Dale, Edna Y Chiang, David L Hasty, Harry S Courtney

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Functional and Proteomic Analysis ofFrontiers in microbiology · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cutting edge issues in rheumatic fever.Clinical reviews in allergy & immunology · 2012
    Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

James B DaleDepartment of Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA. james.dale@med.va.gov
Edna Y Chiang
David L Hasty
Harry S Courtney
University of Tennessee Health Science Center · US

Funding

Chemistry and Immunology of Streptococcal M ProteinsR37AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1986 to 2010
$3.3M
Vaccine Prevention of Group A Streptococcal InfectionsR01AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1985 to 2016
$2.4M
CHEMISTRY AND IMMUNOLOGY OF STREPTOCOCCAL M PROTEINSR55AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1991 to 1991
–
NIAID NIH HHS AI-10085NIAID NIH HHS R01 AI010085NIAID NIH HHS R37 AI010085
6 · The paper itself

Abstract

Virtually all group A streptococci (GAS) produce streptolysin S (SLS), a cytolytic toxin that is responsible for the beta-hemolysis surrounding colonies of the organisms grown on blood agar. SLS is an important virulence determinant of GAS, and recent studies have identified a nine-gene locus that is responsible for synthesis and transport of the toxin. SLS is not immunogenic; thus, no neutralizing antibodies are evoked during the course of natural infection. In the present study, we show that a synthetic peptide containing amino acid residues 10 to 30 of the putative SLS (SagA) propeptide [SLS(10-30)] coupled to keyhole limpet hemocyanin evoked antibodies in rabbits that completely neutralized the hemolytic activity of the toxin in vitro. Inhibition of hemolysis was reversed by preincubation of the immune serum with soluble, unconjugated peptide, indicating the specificity of the antibodies. In addition, antibodies that were affinity purified over an SLS(10-30) peptide column completely inhibited SLS-mediated hemolysis. The SLS(10-30) antisera did not opsonize group A streptococci; however, when combined with type-specific M protein antisera, the SLS antibodies significantly enhanced phagocytosis mediated by M protein antibodies. Thus, we have shown for the first time that it is possible to raise neutralizing antibodies against one of the most potent bacterial cytolytic toxins known. Our data also provide convincing evidence that the sagA gene actually encodes the SLS peptide of GAS. The synthetic peptide may prove to be an important component of vaccines designed to prevent GAS infections.

Indexed as

Antigens, BacterialBacterial ProteinsAmino Acid SequenceAnimalsAntibodies, BacterialAntibody SpecificityBacterial Outer Membrane ProteinsCarrier ProteinsImmune SeraMolecular Sequence DataPhagocytosisRabbitsStreptococcal VaccinesStreptococcus pyogenesStreptolysinsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsCarrier ProteinsImmune Serastreptococcal M proteinStreptococcal Vaccinesstreptolysin SStreptolysins

Identifiers

PMID11895983
PMCPMC127879
OpenAlexW2001643095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.